Karoline Munson
Optometrist · Frankfort, KYNPI 1881698504
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $19,413 of the $26,064 with a category attached, or 74.5%. AbbVie accounts for 86.6% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2022 at $9,490 and has fallen 94.2% since, to $547 in 2025. Among optometrist clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 256 payments — averaging $101.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$23K
- Sun Pharmaceutical Industries Inc.$747
- Alcon$678
- Coopervision Inc.$434
- Bausch & Lomb Americas Inc.$410
- Bausch & Lomb, A Division Of Bausch Health US, LLC$259
- plus $976 from 13 others
What the payments were for
- Speaking & faculty fees$19,41374%
- Travel & lodging$1,5716%
- Food & beverage$5,06019%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 120 | $22,560 |
| Sun Pharmaceutical Industries Inc. | 32 | $747 |
| Alcon | 25 | $678 |
| Coopervision Inc. | 16 | $434 |
| Bausch & Lomb Americas Inc. | 12 | $410 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 10 | $259 |
| Oyster Point Pharma, Inc. | 8 | $148 |
| Astellas Pharma US Inc | 1 | $131 |
| LKC Technologies, Inc. | 1 | $123 |
| Novartis | 7 | $116 |
| Tarsus Pharmaceuticals, Inc. | 5 | $106 |
| ABB Con-cise Optical Group LLC | 5 | $95 |
| Biotissue Holdings Inc. | 5 | $92 |
| Shire North American Group Inc | 2 | $34 |
| Kala Pharmaceuticals, Inc. | 2 | $33 |
| Harrow Eye, LLC | 2 | $33 |
| Dompe US, Inc. | 1 | $27 |
| Johnson & Johnson Vision Care, Inc. | 1 | $22 |
| Aerie Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RESTASIS$8,374
- VUITY$8,051
- RESTASIS MULTIDOSE$4,414
- TOTAL30$300
- INFUSE$118
- CEQUA$114
- BIOTRUE ONE DAY$102
How this compares
$26,064 in reported general payments places this provider in the 95th percentile of 712 optometrist providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 162 | $239,266 |
| CequaCyclosporine | 47 | $70,092 |
| LumiganBimatoprost | 110 | $67,128 |
| XiidraLifitegrast | 39 | $56,293 |
| Cyclosporine | 47 | $47,866 |
| MieboPerfluorohexyloctane/Pf | 60 | $45,492 |
| XdemvyLotilaner | 20 | $36,687 |
| TyrvayaVarenicline Tartrate | 24 | $19,350 |
| VevyeCyclosporine | 20 | $16,215 |
| CombiganBrimonidine Tartrate/Timolol | 38 | $16,116 |
| EysuvisLoteprednol Etabonate | 19 | $9,135 |
| Cosopt PfDorzolamide/Timolol/Pf | 24 | $5,474 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 20 | $5,195 |
| Prednisolone Acetate | 49 | $1,722 |
| Latanoprost | 87 | $1,406 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $22,560 | $322,511310 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $410 | $101,78599 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $747 | $70,09247 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $106 | $36,68720 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $148 | $19,35024 claims |
| Harrow Eye, LLCVevye | $33 | $16,21520 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $33 | $9,13519 claims |
| AlconSimbrinza | $678 | $5,19520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 712 optometrist providers in Kentucky.
Other optometrist in Frankfort
- Lance LongFrankfort$10K
- Kevin StallardFrankfort$7K
- Paul KarpeckiLexington$3.6M
- Bilal AhmadLexington$150K
- Clay MattsonNicholasville$93K
- Ben LeonardCalvert City$75K
- Lee PeplinskiLouisville$74K
- Austin LifferthLouisville$72K
- Christopher KucLexington$52K
- Kristine Kerestan GarbigWilder$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.